Janssen seeks US, EU nod for siltuximab in rare lymph node disease
This article was originally published in Scrip
Executive Summary
Janssen is seeking US and European approval of the company's experimental drug siltuximab (CNTO 328) as a treatment in HIV-negative and human herpes virus-8 (HHV-8)-negative patients with multicentric Castleman disease (MCD), a rare disorder in which lymphocytes are over-produced and lead to an enlargement of the lymph nodes, which results in a weakened immune system, making it harder to fight infections.